Skip to main content
Hit enter to search or ESC to close
Close Search
Origin Branding
search
Menu
  • Home
  • Services
    • Branding
  • Industries
    • Agricultural
    • Animal Health
    • Consumer
    • Industrial
    • Medical Devices
    • Pharmaceutical
    • Technology
  • Views
  • About
    • The Team
    • Why Choose Us?
  • Contact
  • +44 (0) 208 941 5811
  • search

Sanofi – Sarclisa

Sanofi recently announced FDA approval for Sarclisa® (isatuximab-irfc) a monoclonal antibody (mAb) and CD-38 inhibitor for the treatment of relapsed, refractory multiple myeloma (RRMM).

The therapy is approved in combination with pomalidomide and dexamethasone (pom-dex). This combination offers an important new treatment option for patients in the United States living with this incurable disease.

Sarclisa® has Orphan Drug Designation status from both the FDA and the European Medicines Agency (EMA).

The name Sarclisa®, created by Origin is powerful, confident and re-assuring, derived from isatuximab and ‘targeted’, it is active sounding and conveys selectivity, care and strength, whilst being easy to pronounce and recall.

Origin have a strong representation of created brand names across the Oncology therapy area and more broadly the pharmaceutical spectrum and Sarclisa® provides another strong example of the type of name that can be achieved.

  • Previous Project
  • Next Project

United Kingdom

Hampton Court

Bridge House
72 Bridge Road
East Molesey
KT8 9HF

Tel: +44 (0) 20 8941 5811

United States

Birmingham, Michigan

200 Elm Street
Birmingham
Michigan
48009

Tel: +1 248 723 7833

Our Latest Views

  • Why are vaccines important in drug development? May 4, 2022
  • Very Scary Brand Names – not created by Origin November 12, 2021
  • Change Has Happened – Questions Your Brand Team Should Be Asking May 21, 2021

© 2022 Origin Branding.

  • facebook
  • linkedin
Close Menu
  • Home
  • Services
    • Branding
  • Industries
    • Agricultural
    • Animal Health
    • Consumer
    • Industrial
    • Medical Devices
    • Pharmaceutical
    • Technology
  • Views
  • About
    • The Team
    • Why Choose Us?
  • Contact
  • +44 (0) 208 941 5811